The Predictive Effect of the 8th AJCC Pathological Prognostic Staging on the Benefit of Postmastectomy Radiotherapy in N2/N3 Breast Cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66. doi:10.1038/s41572-019-0111-2
   PubMed Web of Science ®Google Scholar
• Regan MM. Risk stratification according to stage and pathology. Breast. 2019;48(Suppl 1):S23–S25. doi:10.1016/S0960-9776(19)31117-8
   PubMedGoogle Scholar
• Plichta JK, Campbell BM, Mittendorf EA, et al. Anatomy and breast cancer staging: is it still relevant? Surg Oncol Clin N Am. 2018;27(1):51–67. doi:10.1016/j.soc.2017.07.010
   PubMed Web of Science ®Google Scholar
• Weiss A, King TA, Hunt KK, et al. Incorporating biologic factors into the american joint committee on cancer breast cancer staging system: review of the supporting evidence. Surg Clin North Am. 2018;98(4):687–702. doi:10.1016/j.suc.2018.03.005
   PubMed Web of Science ®Google Scholar
• Giuliano AE, Connolly JL, Edge SB, et al. Breast cancer-major changes in the american joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(4):290–303. doi:10.3322/caac.21393
   PubMed Web of Science ®Google Scholar
• Kim EJ, Park HS, Kim JY, et al. Assessment of the prognostic staging system of american joint committee on cancer 8th edition for breast cancer: comparisons with the conventional anatomic staging system. J Breast Cancer. 2020;23(1):59–68. doi:10.4048/jbc.2020.23.e9
   PubMed Web of Science ®Google Scholar
• Wang M, Chen H, Wu K, et al. Evaluation of the prognostic stage in the 8th edition of the American Joint Committee on Cancer in locally advanced breast cancer: an analysis based on SEER 18 database. Breast. 2018;37:56–63. doi:10.1016/j.breast.2017.10.011
   PubMed Web of Science ®Google Scholar
• Kurundkar A, Gao X, Zhang K, et al. Comparison of AJCC anatomic and clinical prognostic stage groups in breast cancer: analysis of 3322 cases from a single institution. Clin Breast Cancer. 2018;18(6):e1347–e1352. doi:10.1016/j.clbc.2018.07.013
   PubMed Web of Science ®Google Scholar
• Plichta JK, Ren Y, Thomas SM, et al. Implications for breast cancer restaging based on the 8th edition ajcc staging manual. Ann Surg. 2020;271(1):169–176. doi:10.1097/SLA.0000000000003071
   PubMed Web of Science ®Google Scholar
• Wu SG, Wang J, Lei J, et al. Prognostic validation and therapeutic decision-making of the AJCC eighth pathological prognostic staging for T3N0 breast cancer after mastectomy. Clin Transl Med. 2020;10(1):125–136. doi:10.1002/ctm2.3
   PubMed Web of Science ®Google Scholar
• Wu SG, Wang J, Lian CL, et al. Evaluation of the 8th edition of the American joint committee on cancer’s pathological staging system in prognosis assessment and treatment decision making for stage T1-2N1 breast cancer after mastectomy. Breast. 2020;51:2–10. doi:10.1016/j.breast.2020.02.012
   PubMed Web of Science ®Google Scholar
• Hu J, Fung MW, Tsang JY, et al. Improved prognostication for the updated ajcc breast cancer pathological prognostic staging varied in higher-stage groups. Clin Breast Cancer. 2020;20(3):253–261.e7. doi:10.1016/j.clbc.2020.01.011
   PubMed Web of Science ®Google Scholar
• Savage P, Yu N, Dumitra S, et al. The effect of the American Joint Committee on cancer eighth edition on breast cancer staging and prognostication. Eur J Surg Oncol. 2019;45(10):1817–1820. doi:10.1016/j.ejso.2019.03.027
   PubMed Web of Science ®Google Scholar
• Cervera-Bonilla S, Rodríguez-Ossa P, Vallejo-Ortega M, et al. Evaluation of the AJCC eighth-edition prognostic staging system for breast cancer in a Latin American Cohort. Ann Surg Oncol. 2021. doi:10.1245/s10434-021-09907-x
   Web of Science ®Google Scholar
• Shao N, Xie C, Shi Y, et al. Comparison of the 7th and 8th edition of American Joint Committee on Cancer (AJCC) staging systems for breast cancer patients: a Surveillance, Epidemiology and End Results (SEER) Analysis. Cancer Manag Res. 2019;11:1433–1442. doi:10.2147/CMAR.S185212
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast. clinical practice guidelines in oncology: breast; 2021.
   Google Scholar
• McGale P, Taylor C, Correa C,et al.; Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–2135. doi:10.1016/S0140-6736(14)60488-8
   PubMed Web of Science ®Google Scholar
• Shi Z, Peddi P, Burton G, et al. Effect of postmastectomy radiation on survival of AJCC pN2/N3 breast cancer patients. Anticancer Res. 2016;36(1):261–269.
   PubMed Web of Science ®Google Scholar
• Kyndi M, Sørensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26(9):1419–1426. doi:10.1200/JCO.2007.14.5565
   PubMed Web of Science ®Google Scholar
• Wu SG, He ZY, Li Q, et al. Predictive value of breast cancer molecular subtypes in Chinese patients with four or more positive nodes after postmastectomy radiotherapy. Breast. 2012;21(5):657–661. doi:10.1016/j.breast.2012.07.004
   PubMed Web of Science ®Google Scholar
• Wang SL, Li YX, Song YW, et al. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy. Int J Radiat Oncol Biol Phys. 2011;80(4):1095–1101. doi:10.1016/j.ijrobp.2010.03.038
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) program SEER*stat database: incidence - SEER research plus data, 18 registries, Nov 2020 sub (2000–2018) - linked to county attributes - total U.S., 1969–2019 counties, National Cancer Institute, DCCPS, surveillance research program, released April 2021, based on the November 2020 submission. Available from: www.seer.cancer.gov. Accessed May 9, 2022.
   Google Scholar
• Akaike H. A new look at the statistical model identifcation. IEEE Trans Aut Control. 1974;19:716–723. doi:10.1109/TAC.1974.1100705
   Web of Science ®Google Scholar
• Kang L, Chen W, Petrick NA, et al. Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach. Stat Med. 2015;34(4):685–703. doi:10.1002/sim.6370
   PubMed Web of Science ®Google Scholar
• Weiss A, Chavez-MacGregor M, Lichtensztajn DY, et al. Validation study of the American Joint Committee on cancer eighth edition prognostic stage compared with the anatomic stage in breast cancer. JAMA Oncol. 2018;4(2):203–209. doi:10.1001/jamaoncol.2017.4298
   PubMed Web of Science ®Google Scholar
• Recht A, Comen EA, Fine RE, et al. Postmastectomy radiotherapy: an American society of clinical oncology, American society for radiation oncology, and society of surgical oncology focused guideline update. Pract Radiat Oncol. 2016;6(6):e219–e234. doi:10.1016/j.prro.2016.08.009
   PubMed Web of Science ®Google Scholar
• Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–1220. doi:10.1093/annonc/mdz173
   PubMed Web of Science ®Google Scholar
• Chu QD, Caldito G, Miller JK, et al. Postmastectomy radiation for N2/N3 breast cancer: factors associated with low compliance rate. J Am Coll Surg. 2015;220(4):659–669. doi:10.1016/j.jamcollsurg.2014.12.045
   PubMed Web of Science ®Google Scholar
• Jagsi R, Abrahamse P, Hawley ST, et al. Underascertainment of radiotherapy receipt in surveillance, epidemiology, and end results registry data. Cancer. 2012;118(2):333–341. doi:10.1002/cncr.26295
   PubMed Web of Science ®Google Scholar
• AJCC. Cancer Staging Manual. 8th ed. New York: Springer International Publishing; 2016.
   Google Scholar
• Eaglehouse YL, Manjelievskaia J, Shao S, et al. Costs for breast cancer care in the military health system: an analysis by benefit type and care source. Mil Med. 2018;183(11–12):e500–e508. doi:10.1093/milmed/usy052
   PubMed Web of Science ®Google Scholar
• Darvish L, Ghorbani M, Teshnizi SH, et al. Evaluation of thyroid gland as an organ at risk after breast cancer radiotherapy: a systematic review and meta-analysis. Clin Transl Oncol. 2018;20(11):1430–1438. doi:10.1007/s12094-018-1875-7
   PubMed Web of Science ®Google Scholar
• Ng J, Shuryak I, Xu Y, et al. Predicting the risk of secondary lung malignancies associated with whole-breast radiation therapy. Int J Radiat Oncol Biol Phys. 2012;83(4):1101–1106. doi:10.1016/j.ijrobp.2011.09.052
   PubMed Web of Science ®Google Scholar
• van den Bogaard VA, Ta BD, van der Schaaf A, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. J Clin Oncol. 2017;35(11):1171–1178. doi:10.1200/JCO.2016.69.8480
   PubMed Web of Science ®Google Scholar
• Golubnitschaja O, Liskova A, Koklesova L, et al. Caution, “normal” BMI: health risks associated with potentially masked individual underweight-EPMA position paper 2021. EPMA J. 2021;12(3):243–264. doi:10.1007/s13167-021-00251-4
   PubMed Web of Science ®Google Scholar
• Golubnitschaja O, Filep N, Yeghiazaryan K, et al. Multi-omic approach decodes paradoxes of the triple-negative breast cancer: lessons for predictive, preventive and personalised medicine. Amino Acids. 2018;50(3–4):383–395. doi:10.1007/s00726-017-2524-0
   PubMed Web of Science ®Google Scholar
• Crigna AT, Samec M, Koklesova L, et al. Cell-free nucleic acid patterns in disease prediction and monitoring-hype or hope? EPMA J. 2020;11(4):1–25. doi:10.1007/s13167-020-00226-x
   Web of Science ®Google Scholar
• Zhan X, Li J, Guo Y, et al. Mass spectrometry analysis of human tear fluid biomarkers specific for ocular and systemic diseases in the context of 3P medicine. EPMA J. 2021;12(4):449–475. doi:10.1007/s13167-021-00265-y
   PubMed Web of Science ®Google Scholar
• de Souza JA, Hunt B, Asirwa FC, et al. Global health equity: cancer care outcome disparities in high-, middle-, and low-income countries. J Clin Oncol. 2016;34(1):6–13. doi:10.1200/JCO.2015.62.2860
   PubMed Web of Science ®Google Scholar